Sunshine Biopharma Inc SBFM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SBFM is a good fit for your portfolio.
News
-
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
-
Sunshine Biopharma Announces Reverse Stock Split
-
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
-
Thinking about buying stock in Mediwound, AeroVironment, Airship AI, Lyell Immunopharma, or Sunshine Biopharma?
-
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
-
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
Trading Information
- Previous Close Price
- $0.81
- Day Range
- $0.76–1.19
- 52-Week Range
- $0.75–140.00
- Bid/Ask
- $1.00 / $1.02
- Market Cap
- $1.00 Mil
- Volume/Avg
- 29.6 Mil / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 44
Valuation
|
Metric
|
SBFM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.02 |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
SBFM
Financial Strength
|
Metric
|
SBFM
|
|---|---|
Quick Ratio | 3.39 |
Current Ratio | 4.48 |
Interest Coverage | −34.85 |
Quick Ratio
SBFM
Profitability
|
Metric
|
SBFM
|
|---|---|
Return on Assets (Normalized) | −16.13% |
Return on Equity (Normalized) | −20.99% |
Return on Invested Capital (Normalized) | −22.72% |
Return on Assets
SBFM
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Vfbmnqkcgq | Dgmmlxw | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Bnqnvlmkzl | Yzpz | $68.9 Bil | |
HLN
| Haleon PLC ADR | Gdbrmmn | Wcvx | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lmqqmwsv | Khkb | $14.8 Bil | |
VTRS
| Viatris Inc | Lyxsthgm | Kndd | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Kpsbrcbcy | Knnm | $11.9 Bil | |
CTLT
| Catalent Inc | Hlplybp | Rbtkrt | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Ffzwctcq | Scvp | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Jhldqbkq | Nsrt | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jvbrsjhfm | Gymqzf | $3.5 Bil |